10 February 2016 in Proceedings of the National Academy of Sciences
Significance: The systematic discovery of new gene and drug combinations that modulate complex biological phenotypes and human diseases requires scalable and multiplexed screening technologies. We leverage the programmability of the CRISPR-Cas9 system for multiplexed targeting of specific genomic loci and the versatility of the combinatorial genetics en masse (CombiGEM) technology to rapidly assemble barcoded combinatorial genetic perturbation libraries that can be tracked with high-throughput sequencing. CombiGEM-CRISPR enables simple, massively parallel screening of barcoded combinatorial gene perturbations in human cells, and the translation of these hits into effective drug combinations. This approach is broadly applicable for performing pooled combinatorial genetic perturbations to map out how the orchestrated action of genes controls complex phenotypes and to translate these findings into novel drug combinations.
17 April 2011 in Nature Cell Biology
14 October 2012 in Nature Neuroscience
1 November 2011 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
15 July 2019 in Nature Methods
1 September 2015 in Nature Biotechnology